Company news: Novartis and Boehringer Ingelheim

Share this article:
Novartis is setting itself up to dominate the generic dermatology market. The company said Thursday that generics subsidiary Sandoz is purchasing Fougera Pharmaceuticals for $1.5 billion in cash. The company estimated the merged businesses will have about $620 million in generic dermatology sales, the majority of which will be in the US.

Boehringer Ingelheim launched what it called the largest observational study of non-valvular atrial fibrillation (NVAF) patients. The goal is to enroll 56,000 patients from 50 countries and fill all 56,000 slots by the next decade. NVAF is a form of atrial fibrillation, which is known as an irregular heartbeat but which is also linked to stroke-causing blood clots. A registry, known as GLORIA-AF, will track the long-term impact of anti-clotting treatments, including warfarin, acetylsalicylic acid, BI's anticoagulant Pradaxa (dabigatran etexilate mesylate) and J&J/Bayer's blood thinner Xarelto (rivaroxaban).
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.